All Publications

  • Increased COVID-19 Breakthrough Infection Risk in Patients with Plasma Cell Disorders. Blood La, J., Wu, J. T., Branch-Elliman, W., Huhmann, L., Han, S. S., Brophy, M. T., Do, N. V., Lin, A. Y., Fillmore, N. R., Munshi, N. C. 2022

    View details for DOI 10.1182/blood.2022016317

    View details for PubMedID 35605185

  • Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. Open forum infectious diseases Satyanarayana, G., Enriquez, K. T., Sun, T., Klein, E. J., Abidi, M., Advani, S. M., Awosika, J., Bakouny, Z., Bashir, B., Berg, S., Bernardes, M., Egan, P. C., Elkrief, A., Feldman, L. E., Friese, C. R., Goel, S., Gomez, C. G., Grant, K. L., Griffiths, E. A., Gulati, S., Gupta, S., Hwang, C., Jain, J., Jani, C., Kaltsas, A., Kasi, A., Khan, H., Knox, N., Koshkin, V. S., Kwon, D. H., Labaki, C., Lyman, G. H., McKay, R. R., McNair, C., Nagaraj, G., Nakasone, E. S., Nguyen, R., Nonato, T. K., Olszewski, A. J., Panagiotou, O. A., Puc, M., Razavi, P., Robilotti, E. V., Santos-Dutra, M., Schmidt, A. L., Shah, D. P., Shah, S. A., Vieira, K., Weissmann, L. B., Wise-Draper, T. M., Wu, U., Wu, J. T., Choueiri, T. K., Mishra, S., Warner, J. L., French, B., Farmakiotis, D. 2022; 9 (3): ofac037


    Background: The frequency of coinfections and their association with outcomes have not been adequately studied among patients with cancer and coronavirus disease 2019 (COVID-19), a high-risk group for coinfection.Methods: We included adult (≥18 years) patients with active or prior hematologic or invasive solid malignancies and laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection, using data from the COVID-19 and Cancer Consortium (CCC19, NCT04354701). We captured coinfections within ±2 weeks from diagnosis of COVID-19, identified factors cross-sectionally associated with risk of coinfection, and quantified the association of coinfections with 30-day mortality.Results: Among 8765 patients (hospitalized or not; median age, 65 years; 47.4% male), 16.6% developed coinfections: 12.1% bacterial, 2.1% viral, 0.9% fungal. An additional 6.4% only had clinical diagnosis of a coinfection. The adjusted risk of any coinfection was positively associated with age >50 years, male sex, cardiovascular, pulmonary, and renal comorbidities, diabetes, hematologic malignancy, multiple malignancies, Eastern Cooperative Oncology Group Performance Status, progressing cancer, recent cytotoxic chemotherapy, and baseline corticosteroids; the adjusted risk of superinfection was positively associated with tocilizumab administration. Among hospitalized patients, high neutrophil count and C-reactive protein were positively associated with bacterial coinfection risk, and high or low neutrophil count with fungal coinfection risk. Adjusted mortality rates were significantly higher among patients with bacterial (odds ratio [OR], 1.61; 95% CI, 1.33-1.95) and fungal (OR, 2.20; 95% CI, 1.28-3.76) coinfections.Conclusions: Viral and fungal coinfections are infrequent among patients with cancer and COVID-19, with the latter associated with very high mortality rates. Clinical and laboratory parameters can be used to guide early empiric antimicrobial therapy, which may improve clinical outcomes.

    View details for DOI 10.1093/ofid/ofac037

    View details for PubMedID 35198648

  • Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer. Translational lung cancer research Chao, Y., Zhou, J., Hsu, S., Ding, N., Li, J., Zhang, Y., Xu, X., Tang, X., Wei, T., Zhu, Z., Chu, Q., Neal, J. W., Wu, J. T., Song, Y., Hu, J. 2022; 11 (2): 295-306


    Immune checkpoint inhibitors (ICIs) have led to dramatic improvements in survival a subset of patients with non-small cell lung cancer (NSCLC); however, they have been shown to cause life-threatening toxicity such as immune checkpoint inhibitor-related pneumonitis (CIP). Our previous studies have shown that chronic obstructive pulmonary disease (COPD) and circulating cytokines are associated with clinical outcomes in NSCLC patients receiving ICIs. However, the relationship between these factors and the development of CIP is unclear. In this study, we retrospectively assessed NSCLC patients receiving ICIs to identify CIP risk factors.This retrospective cohort study reviewed medical records of NSCLC patients receiving ICIs targeting programmed cell death 1 (PD-1) or its ligand PD-L1 between March 2017 and December 2020 at Zhongshan Hospital Fudan University. CIP was diagnosed by the treating investigator. Clinical characteristics and baseline plasma cytokines were collected. Logistic regression was used to compare clinical characteristics and circulating cytokine levels between patients with and without CIP to identify CIP risk factors.Of 164 NSCLC patients who received ICIs, CIP developed in 20 cases (12.2%). The presence of COPD [odds ratio (OR), 7.194; 95% confidence interval (CI): 1.130 to 45.798; P=0.037] and PD-L1 expression of ≥50% (OR, 7.184; 95% CI: 1.154 to 44.721; P=0.035) were independently associated with a higher incidence of CIP, whereas a higher baseline level of interleukin-8 (IL-8) was associated with a lower incidence of CIP (OR, 0.758; 95% CI: 0.587 to 0.978; P=0.033). The independent risk factors from final multivariate analysis were incorporated into a nomogram to predict the incidence of CIP. The nomogram model receiver operating characteristic (ROC) curve had a good predictive accuracy of 0.883 (95% CI: 0.806 to 0.959).Increased risk of CIP independently associated with history of COPD, tumor PD-L1 expression ≥50%, and low baseline IL-8 level. The nomogram may hold promise for CIP risk assessment in the administration of ICIs.

    View details for DOI 10.21037/tlcr-22-72

    View details for PubMedID 35280322

    View details for PubMedCentralID PMC8902097

  • Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. JAMA network open Hawley, J. E., Sun, T., Chism, D. D., Duma, N., Fu, J. C., Gatson, N. T., Mishra, S., Nguyen, R. H., Reid, S. A., Serrano, O. K., Singh, S. R., Venepalli, N. K., Bakouny, Z., Bashir, B., Bilen, M. A., Caimi, P. F., Choueiri, T. K., Dawsey, S. J., Fecher, L. A., Flora, D. B., Friese, C. R., Glover, M. J., Gonzalez, C. J., Goyal, S., Halfdanarson, T. R., Hershman, D. L., Khan, H., Labaki, C., Lewis, M. A., McKay, R. R., Messing, I., Pennell, N. A., Puc, M., Ravindranathan, D., Rhodes, T. D., Rivera, A. V., Roller, J., Schwartz, G. K., Shah, S. A., Shaya, J. A., Streckfuss, M., Thompson, M. A., Wulff-Burchfield, E. M., Xie, Z., Yu, P. P., Warner, J. L., Shah, D. P., French, B., Hwang, C., COVID-19 and Cancer Consortium (CCC19), Halmos, B., Verma, A. K., Gartrell, B. A., Goel, S., Ohri, N., Sica, R. A., Thakkar, A., Stockerl-Goldstein, K. E., Butt, O., Campian, J. L., Fiala, M. A., Henderson, J. P., Monahan, R., Zhou, A. Y., Thompson, M. A., Bohachek, P., Mundt, D., Streckfuss, M., Tadesse, E., Lammers, P. E., Panagiotou, O. A., Egan, P. C., Farmakiotis, D., Khan, H., Olszewski, A. J., Loaiza-Bonilla, A., Del Prete, S. A., Bar, M. H., Gulati, A. P., Steve Lo, K. M., Rose, S. J., Stratton, J., Weinstein, P. L., Caimi, P. F., Barnholtz-Sloan, J. S., Garcia, J. A., Nakayama, J. M., Gupta, S., Pennell, N. A., Ahluwalia, M. S., Dawsey, S. J., Lemmon, C. A., Nizam, A., Hoppenot, C., Li, A., Choueiri, T. K., Bakouny, Z., Bouchard, G., Busser, F. J., Connors, J. M., Curran, C. R., Demetri, G. D., Giordano, A., Kelleher, K., Nohria, A., Schmidt, A., Shaw, G., Van Allen, E., Vitale, P., Xu, V., Zon, R. L., Zhang, T., Halabi, S., Leighton, J. C., Lyman, G. H., Graber, J. J., Grivas, P., Khaki, A. R., Loggers, E. T., Lynch, R. C., Nakasone, E. S., Schweizer, M. T., Tachiki, L., Vinayak, S., Wagner, M. J., Yeh, A., Gatson, N. T., Goyal, S., Huynh-Le, M., Rosenstein, L. J., Yu, P. P., Clement, J. M., Daher, A., Dailey, M., Elias, R., Jayaraj, A., Hsu, E., Menendez, A. G., Rathmann, J., Serrano, O., Hwang, C., Gadgeel, S. M., Singh, S. R., Hawley, J. E., Hershman, D., Accordino, M. K., Bhutani, D., Schwartz, G. K., Reuben, D. Y., Alexander, M., Mushtaq, S., Bernicker, E. H., Deeken, J., Shafer, D., Lewis, M. A., Rhodes, T. D., Gill, D. M., Low, C. A., Mashru, S. H., Mansoor, A., Zaren, H. A., Smith, S. J., Nagaraj, G., Akhtari, M., Lau, E., Reeves, M. E., Berg, S., Elms, D., Morgans, A. K., Wehbe, F. H., Altman, J., Gurley, M., Mulcahy, M. F., Durbin, E. B., Kulkarni, A. A., Nelson, H. H., Sachs, Z., Shah, S., Rosovsky, R. P., Reynolds, K., Bardia, A., Boland, G., Gainor, J., Zubiri, L., Halfdanarson, T. R., Bekaii-Saab, T., Desai, A., Xie, Z., Mesa, R. A., Bonnen, M., Mahadevan, D., Ramirez, A. G., Salazar, M., Shah, D. P., Shah, P. K., Faller, B., McKay, R. R., Ajmera, A., Brouha, S. S., Cabal, A., Hsiao, A., Kligerman, S., Shaya, J. A., Weissmann, L. B., Jani, C., Thomson, C. C., Knoble, J., Glace, M. G., Rink, C., Stauffer, K., Zacks, R., Blau, S., Joshi, M., Menon, H., Rovito, M. A., Griffiths, E. A., Elshoury, A., Jabbour, S. K., Misdary, C. F., Shah, M. R., Bashir, B., McNair, C., Mahmood, S. Z., Mico, V., Rivera, A. V., Flora, D. B., Logan, B. B., Kloecker, G., Mandapakala, C., Shah, S. A., Cabebe, E. C., Glover, M. J., Jha, A., Schapira, L., Wu, J. T., Subbiah, S., Lopes, G. d., Revankar, S. G., Stover, D. G., Addison, D., Chen, J. L., Gatti-Mays, M. E., Jhawar, S. R., Karivedu, V., Lustberg, M. B., Palmer, J. D., Wall, S., Williams, N., Wulff-Burchfield, E., Kasi, A., Edwin, N., Smits, M., Chism, D. D., Owenby, S., Doroshow, D. B., Galsky, M. D., Wotman, M., Zhu, H., Fu, J. C., Fazio, A., Sueyoshi, M. H., Huber, K. E., Riess, J., Patel, K. G., Rubinstein, S. M., Wood, W. A., Jensen, C., Kumar, V., Wise-Draper, T. M., Ahmad, S. A., Grover, P., Gulati, S., Kharofa, J., Latif, T., Marcum, M., Park, C., Shaikh, H. G., Bowles, D. W., Geiger, C. L., Markham, M., Bishnoi, R., Russ, A. D., Shah, C., Acoba, J. D., Rho, Y. S., Feldman, L. E., Hoskins, K. F., Gantt, G. J., Liu, L. C., Khan, M., Nguyen, R. H., Pasquinelli, M., Schwartz, C., Venepalli, N. K., Vikas, P., Friese, C. R., Fecher, L. A., Mavromatis, B. H., Bijjula, R. R., Zaman, Q. U., Warner, J. L., Cheng, A., Davis, E. J., Duda, S. N., Enriquez, K. T., French, B., Gillaspie, E. A., Hennessy, C., Hausrath, D., Hsu, C., Johnson, D. B., Li, X., Mishra, S., Reid, S. A., Rini, B. I., Slosky, D. A., Shyr, Y., Solorzano, C. C., Sun, T., Tucker, M. D., Vega-Luna, K., Wang, L. L., Kennecke, H. F., Aboulafia, D. M., Schroeder, B. A., Puc, M., Carducci, T. M., Goldsmith, K. J., Van Loon, S., Topaloglu, U., Alimohamed, S. I., Rice, R. L., Cabalona, W. D., Pilar, C., Peddi, P., Rosen, L. R., McCollough, B. B., Bilen, M. A., Ravindranathan, D., Hafez, N., Herbst, R., LoRusso, P., Masters, T., Stratton, C. 1800; 5 (1): e2142046


    Importance: The COVID-19 pandemic has had a distinct spatiotemporal pattern in the United States. Patients with cancer are at higher risk of severe complications from COVID-19, but it is not well known whether COVID-19 outcomes in this patient population were associated with geography.Objective: To quantify spatiotemporal variation in COVID-19 outcomes among patients with cancer.Design, Setting, and Participants: This registry-based retrospective cohort study included patients with a historical diagnosis of invasive malignant neoplasm and laboratory-confirmed SARS-CoV-2 infection between March and November 2020. Data were collected from cancer care delivery centers in the United States.Exposures: Patient residence was categorized into 9 US census divisions. Cancer center characteristics included academic or community classification, rural-urban continuum code (RUCC), and social vulnerability index.Main Outcomes and Measures: The primary outcome was 30-day all-cause mortality. The secondary composite outcome consisted of receipt of mechanical ventilation, intensive care unit admission, and all-cause death. Multilevel mixed-effects models estimated associations of center-level and census division-level exposures with outcomes after adjustment for patient-level risk factors and quantified variation in adjusted outcomes across centers, census divisions, and calendar time.Results: Data for 4749 patients (median [IQR] age, 66 [56-76] years; 2439 [51.4%] female individuals, 1079 [22.7%] non-Hispanic Black individuals, and 690 [14.5%] Hispanic individuals) were reported from 83 centers in the Northeast (1564 patients [32.9%]), Midwest (1638 [34.5%]), South (894 [18.8%]), and West (653 [13.8%]). After adjustment for patient characteristics, including month of COVID-19 diagnosis, estimated 30-day mortality rates ranged from 5.2% to 26.6% across centers. Patients from centers located in metropolitan areas with population less than 250 000 (RUCC 3) had lower odds of 30-day mortality compared with patients from centers in metropolitan areas with population at least 1 million (RUCC 1) (adjusted odds ratio [aOR], 0.31; 95% CI, 0.11-0.84). The type of center was not significantly associated with primary or secondary outcomes. There were no statistically significant differences in outcome rates across the 9 census divisions, but adjusted mortality rates significantly improved over time (eg, September to November vs March to May: aOR, 0.32; 95% CI, 0.17-0.58).Conclusions and Relevance: In this registry-based cohort study, significant differences in COVID-19 outcomes across US census divisions were not observed. However, substantial heterogeneity in COVID-19 outcomes across cancer care delivery centers was found. Attention to implementing standardized guidelines for the care of patients with cancer and COVID-19 could improve outcomes for these vulnerable patients.

    View details for DOI 10.1001/jamanetworkopen.2021.42046

    View details for PubMedID 34982158

  • Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. Cancer discovery Elkrief, A., Wu, J. T., Jani, C., Enriquez, K. T., Glover, M., Shah, M. R., Shaikh, H. G., Beeghly-Fadiel, A., French, B., Jhawar, S. R., Johnson, D. B., McKay, R. R., Rivera, D. R., Reuben, D. Y., Shah, S., Tinianov, S. L., Vinh, D. C., Mishra, S., Warner, J. L. 2021


    The ongoing COVID-19 pandemic has left patients with current or past history of cancer facing disparate consequences at every stage of the cancer trajectory. This comprehensive review offers a landscape analysis of the current state of the literature on COVID-19 and cancer including the immune response to COVID-19, risk factors for severe disease, and impact of anticancer therapies. We also review the latest data on treatment of COVID-19 and vaccination safety and efficacy in patients with cancer, as well as impact of the pandemic on cancer care, including the urgent need for rapid evidence generation and real-world study designs.

    View details for DOI 10.1158/2159-8290.CD-21-1368

    View details for PubMedID 34893494

  • Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study. JAMA oncology Wu, J. T., La, J., Branch-Elliman, W., Huhmann, L. B., Han, S. S., Parmigiani, G., Tuck, D. P., Brophy, M. T., Do, N. V., Lin, A. Y., Munshi, N. C., Fillmore, N. R. 2021


    Importance: Patients with cancer are at increased risk for severe COVID-19, but it is unknown whether SARS-CoV-2 vaccination is effective for them.Objective: To determine the association between SARS-CoV-2 vaccination and SARS-CoV-2 infections among a population of Veterans Affairs (VA) patients with cancer.Design, Setting, and Participants: Retrospective, multicenter, nationwide cohort study of SARS-CoV-2 vaccination and infection among patients in the VA health care system from December 15, 2020, to May 4, 2021. All adults with solid tumors or hematologic cancer who received systemic cancer-directed therapy from August 15, 2010, to May 4, 2021, and were alive and without a documented SARS-CoV-2 positive result as of December 15, 2020, were eligible for inclusion. Each day between December 15, 2020, and May 4, 2021, newly vaccinated patients were matched 1:1 with unvaccinated or not yet vaccinated controls based on age, race and ethnicity, VA facility, rurality of home address, cancer type, and treatment type/timing.Exposures: Receipt of a SARS-CoV-2 vaccine.Main Outcomes and Measures: The primary outcome was documented SARS-CoV-2 infection. A proxy for vaccine effectiveness was defined as 1 minus the risk ratio of SARS-CoV-2 infection for vaccinated individuals compared with unvaccinated controls.Results: A total of 184 485 patients met eligibility criteria, and 113 796 were vaccinated. Of these, 29 152 vaccinated patients (median [IQR] age, 74.1 [70.2-79.3] years; 95% were men; 71% were non-Hispanic White individuals) were matched 1:1 to unvaccinated or not yet vaccinated controls. As of a median 47 days of follow-up, 436 SARS-CoV-2 infections were detected in the matched cohort (161 infections in vaccinated patients vs 275 in unvaccinated patients). There were 17 COVID-19-related deaths in the vaccinated group vs 27 COVID-19-related deaths in the unvaccinated group. Overall vaccine effectiveness in the matched cohort was 58% (95% CI, 39% to 72%) starting 14 days after the second dose. Patients who received chemotherapy within 3 months prior to the first vaccination dose were estimated to have a vaccine effectiveness of 57% (95% CI, -23% to 90%) starting 14 days after the second dose vs 76% (95% CI, 50% to 91%) for those receiving endocrine therapy and 85% (95% CI, 29% to 100%) for those who had not received systemic therapy for at least 6 months prior.Conclusions and Relevance: In this cohort study, COVID-19 vaccination was associated with lower SARS-CoV-2 infection rates in patients with cancer. Some immunosuppressed subgroups may remain at early risk for COVID-19 despite vaccination, and consideration should be given to additional risk reduction strategies, such as serologic testing for vaccine response and a third vaccine dose to optimize outcomes.

    View details for DOI 10.1001/jamaoncol.2021.5771

    View details for PubMedID 34854921

  • Inadequate Sars-Cov-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study Fillmore, N. R., La, J., Wu, J., Branch-Elliman, W., Huhmann, L., Han, S. S., Parmigiani, G., Tuck, D. P., Brophy, M., Do, N. V., Lin, A. Y., Munshi, N. C. AMER SOC HEMATOLOGY. 2021
  • Development and Validation of a Risk Prediction Tool for Second Primary Lung Cancer. Journal of the National Cancer Institute Choi, E., Sanyal, N., Ding, V. Y., Gardner, R. M., Aredo, J. V., Lee, J., Wu, J. T., Hickey, T. P., Barrett, B., Riley, T. L., Wilkens, L. R., Leung, A. N., Le Marchand, L., Tammemagi, M. C., Hung, R. J., Amos, C. I., Freedman, N. D., Cheng, I., Wakelee, H. A., Han, S. S. 2021


    BACKGROUND: With advancing therapeutics, lung cancer (LC) survivors are rapidly increasing in number. While mounting evidence suggests LC survivors have high risk of second primary lung cancer (SPLC), there is no validated prediction tool available for clinical use to identify high-risk LC survivors for SPLC.METHODS: Using data from 6,325 ever-smokers in the Multiethnic Cohort (MEC) diagnosed with initial primary lung cancer (IPLC) in 1993-2017, we developed a prediction model for 10-year SPLC risk after IPLC diagnosis using cause-specific Cox regression. We evaluated the model's clinical utility using decision curve analysis and externally validated it using two population-based data, PLCO and NLST, that included 2,963 and 2,844 IPLC (101 and 93 SPLC cases), respectively.RESULTS: Over 14,063 person-years, 145 (2.3%) developed SPLC in MEC. Our prediction model demonstrated a high predictive accuracy (Brier score = 2.9, 95% confidence interval [CI] = 2.4-3.3) and discrimination (AUC = 81.9%, 95% CI=78.2%-85.5%) based on bootstrap validation in MEC. Stratification by the estimated risk quartiles showed that the observed SPLC incidence was statistically significantly higher in the 4th versus 1st quartile (9.5% versus 0.2%; P<.001). Decision curve analysis indicated that in a wide range of 10-year risk thresholds from 1% to 20%, the model yielded a larger net-benefit versus hypothetical all-screening or no-screening scenarios. External validation using PLCO and NLST showed an AUC of 78.8% (95% CI=74.6%-82.9%) and 72.7% (95% CI=67.7%-77.7%), respectively.CONCLUSIONS: We developed and validated a SPLC prediction model based on large population-based cohorts. The proposed prediction tool can help identify high-risk LC patients for SPLC and can be incorporated into clinical decision-making for SPLC surveillance and screening.

    View details for DOI 10.1093/jnci/djab138

    View details for PubMedID 34255071

  • Patterns in cancer management changes for patients with COVID-19 in northern California. Glover, M., Wu, J., Kwon, D. H., Zhang, S., Henry, S., Wood, D., Rubin, D., Borno, H., Small, E., Schapira, L., Koshkin, V. S., Shah, S. LIPPINCOTT WILLIAMS & WILKINS. 2021
  • Reply to R. Kebudi et al. JCO oncology practice Tsu-Yu Wu, J., Kwon, D. H., Glover, M., Henry, S., Wood, D., Rubin, D., Koshkin, V., Schapira, L., Shah, S. A. 2021: OP2100105

    View details for DOI 10.1200/OP.21.00105

    View details for PubMedID 33881937

  • Impact of COVID-19 on breast cancer care at a Bay Area academic center Wu, J., Bobo, S., Henry, S., Mills, M., Kurian, A., Dirbas, F. AMER ASSOC CANCER RESEARCH. 2021
  • Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Su, C. C., Wu, J. T., Neal, J. W., Popat, R. A., Kurian, A. W., Backhus, L. M., Nagpal, S., Leung, A. N., Wakelee, H. A., Han, S. S. 2021


    Brain metastasis (BM) is one of the most common metastases from primary lung cancer (PLC). Recently, the National Lung Screening Trial (NLST) demonstrated the efficacy of low-dose computed tomography (LDCT) screening on LC mortality reduction. However, it remains unknown if early detection of PLC through LDCT may be potentially beneficial in reducing the risk of subsequent metastases. Our study aimed to investigate the impact of LDCT screening for PLC on the risk of developing BM after PLC diagnosis.We used NLST data to identify 1,502 participants who were diagnosed with PLC in 2002-2009 and have follow-up data for BM. Cause-specific competing risk regression was applied to evaluate an association between BM risk and the mode of PLC detection-i.e., LDCT screen-detected versus non-LDCT screen-detected. Subgroup analyses were conducted in early-stage PLC patients and those who underwent surgery for PLC.Of 1502 participants, 41.4% had PLC detected through LDCT-screening versus 58.6% detected through other methods, e.g., chest X-Ray or incidental detection. Patients whose PLC was detected with LDCT-screening had a significantly lower 3-year incidence of BM (6.5%) versus those without (11.9%), with a cause-specific hazard ratio (HR) of 0.53 (p=0.001), adjusting for PLC stage, histology, diagnosis age and smoking status. This significant reduction in BM risk among PLCs detected through LDCT-screening persisted in subgroups of early-stage PLC participants (HR 0.47, p=0.002) and those who underwent surgery (HR 0.37, p=0.001).Early detection of PLC using LDCT-screening is associated with lower risk of BM after PLC diagnosis based on a large population-based study.

    View details for DOI 10.1016/j.jtho.2021.05.010

    View details for PubMedID 34091050

  • Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study. Cancer discovery Rivera, D. R., Peters, S., Panagiotou, O. A., Shah, D. P., Kuderer, N. M., Hsu, C., Rubinstein, S. M., Lee, B. J., Choueiri, T. K., de Lima Lopes, G., Grivas, P., Painter, C. A., Rini, B. I., Thompson, M. A., Arcobello, J., Bakouny, Z., Doroshow, D. B., Egan, P. C., Farmakiotis, D., Fecher, L. A., Friese, C. R., Galsky, M. D., Goel, S., Gupta, S., Halfdanarson, T. R., Halmos, B., Hawley, J. E., Khaki, A. R., Lemmon, C. A., Mishra, S., Olszewski, A. J., Pennell, N. A., Puc, M. M., Revankar, S. G., Schapira, L., Schmidt, A., Schwartz, G. K., Shah, S. A., Wu, J. T., Xie, Z., Yeh, A. C., Zhu, H., Shyr, Y., Lyman, G. H., Warner, J. L. 2020


    Among 2,186 US adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality, and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19 treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as white patients. While observational studies can be limited by potential unmeasured confounding, our findings add to the emerging understanding of patterns of care for patients with cancer and COVID-19 and support evaluation of emerging treatments through prospective controlled trials inclusive of this population.

    View details for DOI 10.1158/2159-8290.CD-20-0941

    View details for PubMedID 32699031

  • Opportunities and Challenges for Analyzing Cancer Data at the Inter- and Intra-Institutional Levels JCO PRECISION ONCOLOGY Wu, J., Bryan, J., Rubinstein, S. M., Wang, L., Lenoue-Newton, M., Zuhour, R., Levy, M., Micheel, C., Xu, Y., Bhavnani, S. K., Mackey, L., Warner, J. L. 2020; 4: 743–56


    Our goal was to identify the opportunities and challenges in analyzing data from the American Association of Cancer Research Project Genomics Evidence Neoplasia Information Exchange (GENIE), a multi-institutional database derived from clinically driven genomic testing, at both the inter- and the intra-institutional level. Inter-institutionally, we identified genotypic differences between primary and metastatic tumors across the 3 most represented cancers in GENIE. Intra-institutionally, we analyzed the clinical characteristics of the Vanderbilt-Ingram Cancer Center (VICC) subset of GENIE to inform the interpretation of GENIE as a whole.We performed overall cohort matching on the basis of age, ethnicity, and sex of 13,208 patients stratified by cancer type (breast, colon, or lung) and sample site (primary or metastatic). We then determined whether detected variants, at the gene level, were associated with primary or metastatic tumors. We extracted clinical data for the VICC subset from VICC's clinical data warehouse. Treatment exposures were mapped to a 13-class schema derived from the HemOnc ontology.Across 756 genes, there were significant differences in all cancer types. In breast cancer, ESR1 variants were over-represented in metastatic samples (odds ratio, 5.91; q < 10-6). TP53 mutations were over-represented in metastatic samples across all cancers. VICC had a significantly different cancer type distribution than that of GENIE but patients were well matched with respect to age, sex, and sample type. Treatment data from VICC was used for a bipartite network analysis, demonstrating clusters with a mix of histologies and others being more histology specific.This article demonstrates the feasibility of deriving meaningful insights from GENIE at the inter- and intra-institutional level and illuminates the opportunities and challenges of the data GENIE contains. The results should help guide future development of GENIE, with the goal of fully realizing its potential for accelerating precision medicine.

    View details for DOI 10.1200/PO.19.00394

    View details for Web of Science ID 000615673800001

    View details for PubMedID 32923903

    View details for PubMedCentralID PMC7446524

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet (London, England) Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y. n., Rubinstein, S. M., Rivera, D. R., Shete, S. n., Hsu, C. Y., Desai, A. n., de Lima Lopes, G. n., Grivas, P. n., Painter, C. A., Peters, S. n., Thompson, M. A., Bakouny, Z. n., Batist, G. n., Bekaii-Saab, T. n., Bilen, M. A., Bouganim, N. n., Larroya, M. B., Castellano, D. n., Del Prete, S. A., Doroshow, D. B., Egan, P. C., Elkrief, A. n., Farmakiotis, D. n., Flora, D. n., Galsky, M. D., Glover, M. J., Griffiths, E. A., Gulati, A. P., Gupta, S. n., Hafez, N. n., Halfdanarson, T. R., Hawley, J. E., Hsu, E. n., Kasi, A. n., Khaki, A. R., Lemmon, C. A., Lewis, C. n., Logan, B. n., Masters, T. n., McKay, R. R., Mesa, R. A., Morgans, A. K., Mulcahy, M. F., Panagiotou, O. A., Peddi, P. n., Pennell, N. A., Reynolds, K. n., Rosen, L. R., Rosovsky, R. n., Salazar, M. n., Schmidt, A. n., Shah, S. A., Shaya, J. A., Steinharter, J. n., Stockerl-Goldstein, K. E., Subbiah, S. n., Vinh, D. C., Wehbe, F. H., Weissmann, L. B., Wu, J. T., Wulff-Burchfield, E. n., Xie, Z. n., Yeh, A. n., Yu, P. P., Zhou, A. Y., Zubiri, L. n., Mishra, S. n., Lyman, G. H., Rini, B. I., Warner, J. L. 2020


    Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness.In this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with, NCT04354701, and is ongoing.Of 1035 records entered into the CCC19 database during the study period, 928 patients met inclusion criteria for our analysis. Median age was 66 years (IQR 57-76), 279 (30%) were aged 75 years or older, and 468 (50%) patients were male. The most prevalent malignancies were breast (191 [21%]) and prostate (152 [16%]). 366 (39%) patients were on active anticancer treatment, and 396 (43%) had active (measurable) cancer. At analysis (May 7, 2020), 121 (13%) patients had died. In logistic regression analysis, independent factors associated with increased 30-day mortality, after partial adjustment, were: increased age (per 10 years; partially adjusted odds ratio 1·84, 95% CI 1·53-2·21), male sex (1·63, 1·07-2·48), smoking status (former smoker vs never smoked: 1·60, 1·03-2·47), number of comorbidities (two vs none: 4·50, 1·33-15·28), Eastern Cooperative Oncology Group performance status of 2 or higher (status of 2 vs 0 or 1: 3·89, 2·11-7·18), active cancer (progressing vs remission: 5·20, 2·77-9·77), and receipt of azithromycin plus hydroxychloroquine (vs treatment with neither: 2·93, 1·79-4·79; confounding by indication cannot be excluded). Compared with residence in the US-Northeast, residence in Canada (0·24, 0·07-0·84) or the US-Midwest (0·50, 0·28-0·90) were associated with decreased 30-day all-cause mortality. Race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.Among patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments.American Cancer Society, National Institutes of Health, and Hope Foundation for Cancer Research.

    View details for DOI 10.1016/S0140-6736(20)31187-9

    View details for PubMedID 32473681

  • Changes in Cancer Management due to COVID-19 Illness in Patients with Cancer in Northern California. JCO oncology practice Wu, J. T., Kwon, D. H., Glover, M. J., Henry, S. n., Wood, D. n., Rubin, D. L., Koshkin, V. S., Schapira, L. n., Shah, S. A. 2020: OP2000790


    The response to the COVID-19 pandemic has affected the management of patients with cancer. In this pooled retrospective analysis, we describe changes in management patterns for patients with cancer diagnosed with COVID-19 in two academic institutions in the San Francisco Bay Area.Adult and pediatric patients diagnosed with COVID-19 with a current or historical diagnosis of malignancy were identified from the electronic medical record at the University of California, San Francisco, and Stanford University. The proportion of patients undergoing active cancer management whose care was affected was quantified and analyzed for significant differences with regard to management type, treatment intent, and the time of COVID-19 diagnosis. The duration and characteristics of such changes were compared across subgroups.A total of 131 patients were included, of whom 55 were undergoing active cancer management. Of these, 35 of 55 (64%) had significant changes in management that consisted primarily of delays. An additional three patients not undergoing active cancer management experienced a delay in management after being diagnosed with COVID-19. The decision to change management was correlated with the time of COVID-19 diagnosis, with more delays identified in patients treated with palliative intent earlier in the course of the pandemic (March/April 2020) compared with later (May/June 2020) (OR, 4.2; 95% CI, 1.03 to 17.3; P = .0497). This difference was not seen among patients treated with curative intent during the same timeframe.We found significant changes in the management of cancer patients with COVID-19 treated with curative and palliative intent that evolved over time. Future studies are needed to determine the impact of changes in management and treatment on cancer outcomes for patients with cancer and COVID-19.

    View details for DOI 10.1200/OP.20.00790

    View details for PubMedID 33332170